Plasma Pharmacokinetic Parameters of Dexamethasone Following Administration of a Dexamethasone Intracanalicular Insert in Healthy Adults

References

• Zhang G, Liu S, Yang L, Li Y. The role of dexamethasone in clinical pharmaceutical treatment for patients with cataract surgery. Exp Ther Med. 2018;15(1):2177–2181. doi:10.3892/etm.2017.5639
   Web of Science ®Google Scholar
• Brooks CC, Jabbehdari S, Gupta PK. Dexamethasone 0.4mg sustained-release intracanalicular insert in the management of ocular inflammation and pain following ophthalmic surgery: design, development and place in therapy. Clin Ophthalmol. 2020;14:89–94. doi:10.2147/OPTH.S238756
   Web of Science ®Google Scholar
• Yang CQ, Sun W, Gu YS. A clinical study of the efficacy of topical corticosteroids on dry eye. J Zhejiang Univ Sci B. 2006;7(8):675–678. doi:10.1631/jzus.2006.B0675
   PubMedGoogle Scholar
• Sacchetti M, Abicca I, Bruscolini A, Cavaliere C, Nebbioso M, Lambiase A. Allergic conjunctivitis: current concepts on pathogenesis and management. J Biol Regul Homeost Agents. 2018;32:49–60.
   Google Scholar
• McGhee CN, Dean S, Danesh-Meyer H. Locally administered ocular corticosteroids: benefits and risks. Drug Safety. 2002;25(1):33–55. doi:10.2165/00002018-200225010-00004
   PubMed Web of Science ®Google Scholar
• Rosin LM, Bell NP. Preservative toxicity in glaucoma medication: clinical evaluation of benzalkonium chloride-free 0.5% timolol eye drops. Clin Ophthalmol. 2013;7:2131–2135.
   PubMedGoogle Scholar
• Zhang R, Park M, Richardson A, et al. Dose-dependent benzalkonium chloride toxicity imparts ocular surface epithelial changes with features of dry eye disease. Ocul Surf. 2020;18(1):158–169. doi:10.1016/j.jtos.2019.11.006
   PubMed Web of Science ®Google Scholar
• Singh G, Kaur J. Iatrogenic dry eye: late effect of topical steroid formulations. J Indian Med Assoc. 1992;90:235–237.
   Google Scholar
• Robin A, Grover DS. Compliance and adherence in glaucoma management. Indian J Ophthalmol. 2011;59(7):S93–96. doi:10.4103/0301-4738.73693
   Web of Science ®Google Scholar
• Olthoff CM, Schouten JS, van de Borne BW, Webers CA. Noncompliance with ocular hypotensive treatment in patients with glaucoma or ocular hypertension an evidence-based review. Ophthalmology. 2005;112:953–961. doi:10.1016/j.ophtha.2004.12.035
   PubMed Web of Science ®Google Scholar
• Gomes BF, Paredes AF, Madeira N, Moraes HV, Santhiago MR. Assessment of eye drop instillation technique in glaucoma patients. Arq Bras Oftalmol. 2017;80(4):238–241. doi:10.5935/0004-2749.20170058
   PubMed Web of Science ®Google Scholar
• Gupta R, Patil B, Shah BM, Bali SJ, Mishra SK, Dada T. Evaluating eye drop instillation technique in glaucoma patients. J Glaucoma. 2012;21(3):189–192. doi:10.1097/IJG.0b013e31820bd2e1
   PubMed Web of Science ®Google Scholar
• Solomon A, Chowers I, Raiskup F, Siganos CS, Frucht-Pery J. Inadvertent conjunctival trauma related to contact with drug container tips: a masquerade syndrome. Ophthalmology. 2003;110(4):796–800. doi:10.1016/S0161-6420(02)01967-X
   Web of Science ®Google Scholar
• Sawhney AS, Bassett M, Blizzard C. Drug delivery through hydrogel plugs. US Patent 8409606B2; 2013. Available from: https://patentimages.storage.googleapis.com/8e/df/8d/27cebf6bb8bbee/US8409606.pdf. Accessed April 14, 2021.
   Google Scholar
• Kołodyńska D, Skiba A, Górecka B, Hubicki Z. Hydrogels from fundaments to application. In: Majee SB, editor. Emerging Concepts in Analysis and Applications of Hydrogels. London: IntechOpen Limited; 2016.
   Google Scholar
• Tyson SL, Campbell P, Biggins J, et al. Punctum and canalicular anatomy for hydrogel-based intracanalicular insert technology. Ther Deliv. 2020;11(3):173–182. doi:10.4155/tde-2020-0010
   PubMed Web of Science ®Google Scholar
• Tyson SL, Bafna S, Gira JP, et al. Multicenter randomized phase 3 study of a sustained-release intracanalicular dexamethasone insert for treatment of ocular inflammation and pain after cataract surgery. J Cataract Refract Surg. 2019;45(2):204–212. doi:10.1016/j.jcrs.2018.09.023
   PubMed Web of Science ®Google Scholar
• Walters T, Bafna S, Vold S, et al. Efficacy and safety of sustained release dexamethasone for the treatment of ocular pain and inflammation after cataract surgery: results from two phase 3 studies. J Clin Exp Ophthalmol. 2016;7(4):572.
   Google Scholar
• Ocular Therapeutix, Inc. Dextenza^® (Dexamethasone Insert) for Intracanalicular Use. Prescribing Information. Bedford, MA: Ocular Therapeutix, Inc.; 2019.
   Google Scholar
• Gira JP, Walters TR. Evaluating the patient experience after implantation of a 0.4mg sustained release dexamethasone intracanalicular insert (Dextenza): results of a qualitative survey. Patient Prefer Adherence. 2017;11:487–494. doi:10.2147/PPA.S126283
   Web of Science ®Google Scholar
• Torkildsen G, Abelson MB, Gomes PJ, McLaurin E, Potts SL, Mah FS. Vehicle-controlled, Phase 2 clinical trial of a sustained-release dexamethasone intracanalicular insert in a chronic allergen challenge model. J Ocul Pharmacol Ther. 2017;33(2):79–90. doi:10.1089/jop.2016.0154
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov. OTX-15-002: a Phase 3 study evaluating the safety and efficacy of OTX-DP for the treatment of chronic allergic conjunctivitis. Identifier: NCT02988882. Available from: https://clinicaltrials.gov/ct2/show/NCT02988882?term=ocular+therapeutix&draw=3&rank=17. Accessed April 14, 2021.
   Google Scholar
• World Medical Association. WMA declaration of Helsinki – ethical principles for medical research involving human subjects; 2018. Available from: https://www.wma.net/policies-post/wma-declaration-of-helsinki-ethical-principles-for-medical-research-involving-human-subjects/. Accessed 16 March 2021.
   Google Scholar
• Ocular Therapeutix, Inc. Dextenza^® (Dexamethasone Ophthalmic Insert) 0.4 Mg for Intracanalicular Use [Prescribing Information 2019]. Bedford, MA: Ocular Therapeutix, Inc.; 2019.
   Google Scholar
• Farkouh A, Frigo P, Czejka M. Systemic side effects of eye drops: a pharmacokinetic perspective. Clin Ophthalmol. 2016;10:2433–2441. doi:10.2147/OPTH.S118409
   PubMed Web of Science ®Google Scholar
• Moore DB, Beck J, Kryscio RJ. An objective assessment of the variability in number of drops per bottle of glaucoma medication. BMC Ophthalmol. 2017;17:78. doi:10.1186/s12886-017-0473-8
   PubMed Web of Science ®Google Scholar
• Allergan USA, Inc. Ozurdex^® (Dexamethasone Intravitreal Implant) for Intravitreal Injection [Prescribing Information 2018]. Madison, NJ: Allergan USA, Inc.; 2018.
   Google Scholar
• Weijtens O, Schoemaker RC, Romijn FP, Cohen AF, Lentjes EG, van Meurs JC. Intraocular penetration and systemic absorption after topical application of dexamethasone disodium phosphate. Ophthalmol. 2002;109:1887–1891. doi:10.1016/S0161-6420(02)01176-4
   PubMed Web of Science ®Google Scholar
• Alcon Laboratories, Inc. Tobradex^® ST (Tobramycin/Dexamethasone Ophthalmic Suspension) 0.3%/0.05% [Prescribing Information 2011]. Fort Worth, TX: Alcon Laboratories, Inc.; 2011.
   Google Scholar
• Lee A, Blair HA. Dexamethasone intracanalicular insert: a review in treating post-surgical ocular pain and inflammation. Drugs. 2020;80(11):1101–1108. doi:10.1007/s40265-020-01344-6
   PubMed Web of Science ®Google Scholar